BR112018003588A2 - compostos e composições úteis para tratamento de distúrbios relacionados ao ntrk - Google Patents
compostos e composições úteis para tratamento de distúrbios relacionados ao ntrkInfo
- Publication number
- BR112018003588A2 BR112018003588A2 BR112018003588A BR112018003588A BR112018003588A2 BR 112018003588 A2 BR112018003588 A2 BR 112018003588A2 BR 112018003588 A BR112018003588 A BR 112018003588A BR 112018003588 A BR112018003588 A BR 112018003588A BR 112018003588 A2 BR112018003588 A2 BR 112018003588A2
- Authority
- BR
- Brazil
- Prior art keywords
- ntrk
- treating
- compounds
- related disorders
- compositions useful
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562210264P | 2015-08-26 | 2015-08-26 | |
| PCT/US2016/048698 WO2017035354A1 (en) | 2015-08-26 | 2016-08-25 | Compounds and compositions useful for treating disorders related to ntrk |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018003588A2 true BR112018003588A2 (pt) | 2018-09-25 |
Family
ID=56896780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018003588A BR112018003588A2 (pt) | 2015-08-26 | 2016-08-25 | compostos e composições úteis para tratamento de distúrbios relacionados ao ntrk |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10017512B2 (https=) |
| EP (1) | EP3341374A1 (https=) |
| JP (1) | JP6877407B2 (https=) |
| KR (1) | KR20180043810A (https=) |
| CN (1) | CN108137607B (https=) |
| AR (1) | AR105836A1 (https=) |
| AU (1) | AU2016311426B2 (https=) |
| BR (1) | BR112018003588A2 (https=) |
| CA (1) | CA2995997A1 (https=) |
| HK (1) | HK1255330A1 (https=) |
| IL (1) | IL257702A (https=) |
| MX (1) | MX2018002407A (https=) |
| PH (1) | PH12018500397A1 (https=) |
| RU (1) | RU2744974C2 (https=) |
| TW (1) | TW201713665A (https=) |
| WO (1) | WO2017035354A1 (https=) |
| ZA (1) | ZA201801881B (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201500125QA (en) | 2012-07-11 | 2015-02-27 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
| WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| SI3057969T1 (sl) | 2013-10-17 | 2018-10-30 | Blueprint Medicines Corporation | Sestavki, uporabni za zdravljenje motenj, povezanih s KIT |
| RS63405B1 (sr) | 2013-10-25 | 2022-08-31 | Blueprint Medicines Corp | Inhibitori receptora faktora rasta fibroblasta |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| CN108026102A (zh) | 2015-07-24 | 2018-05-11 | 蓝印药品公司 | 可用于治疗与kit和pdgfr相关的病症的化合物 |
| BR112018003588A2 (pt) | 2015-08-26 | 2018-09-25 | Blueprint Medicines Corp | compostos e composições úteis para tratamento de distúrbios relacionados ao ntrk |
| SI3371171T1 (sl) | 2015-11-02 | 2024-03-29 | Blueprint Medicines Corporation | Inhibitorji ret |
| SG10201912607SA (en) | 2015-11-19 | 2020-02-27 | Blueprint Medicines Corp | Compounds and compositions useful for treating disorders related to ntrk |
| US10183928B2 (en) | 2016-03-17 | 2019-01-22 | Blueprint Medicines Corporation | Inhibitors of RET |
| CN109311889B (zh) | 2016-04-15 | 2021-11-16 | 缆图药品公司 | 激活素受体样激酶抑制剂 |
| US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| WO2018022761A1 (en) | 2016-07-27 | 2018-02-01 | Blueprint Medicines Corporation | Substituted cyclopentane-amides for treating disorders related to ret |
| US11040979B2 (en) | 2017-03-31 | 2021-06-22 | Blueprint Medicines Corporation | Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR |
| CA3071032A1 (en) | 2017-08-23 | 2019-02-28 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Macrocycle containing aminopyrazole and pyrimidine and pharmaceutical composition and use thereof |
| EP3697786B1 (en) | 2017-10-18 | 2022-08-31 | Blueprint Medicines Corporation | Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase |
| WO2019152982A1 (en) * | 2018-02-05 | 2019-08-08 | Shenzhen Ionova Life Science Co., Ltd. | Heterobicyclic compounds as ep4 antagonists |
| WO2019184955A1 (en) * | 2018-03-28 | 2019-10-03 | Fochon Pharmaceuticals, Ltd. | Macrocyclic compounds as trk kinases inhibitors |
| PE20210096A1 (es) | 2018-04-03 | 2021-01-12 | Blueprint Medicines Corp | Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret |
| TW202045480A (zh) * | 2019-02-27 | 2020-12-16 | 美商費洛醫療公司 | 化合物及使用方法 |
| ES2966512T3 (es) | 2019-04-12 | 2024-04-22 | Blueprint Medicines Corp | Formas cristalinas de (S)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1H-pirazol-4-il)pirrolo[2,1-f][1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina y métodos de elaboración |
| FI4065585T3 (fi) * | 2019-11-25 | 2025-09-26 | Alkermes Inc | Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä |
| EP4157829A1 (en) | 2020-05-29 | 2023-04-05 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| CN113408945B (zh) * | 2021-07-15 | 2023-03-24 | 广西中烟工业有限责任公司 | 一种烤烟纯度的检测方法、装置、电子设备及存储介质 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6251911B1 (en) * | 1996-10-02 | 2001-06-26 | Novartis Ag | Pyrimidine derivatives and processes for the preparation thereof |
| PL224879B1 (pl) | 2002-09-04 | 2017-02-28 | Pharmacopeia Drug Discovery Inc | Pirazolo [1,5-a] pirymidynowy związek, jego zastosowanie do wytwarzania leku oraz zawierająca go farmaceutyczna kompozycja |
| US7329662B2 (en) | 2003-10-03 | 2008-02-12 | Hoffmann-La Roche Inc. | Pyrazolo-pyridine |
| EP2168968B1 (en) * | 2004-04-02 | 2017-08-23 | OSI Pharmaceuticals, LLC | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| WO2005117909A2 (en) * | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| AU2008296479A1 (en) * | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
| MY169791A (en) | 2008-10-22 | 2019-05-15 | Array Biopharma Inc | Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| CN102471342A (zh) * | 2010-05-05 | 2012-05-23 | 沃泰克斯药物股份有限公司 | 用作PKC-θ抑制剂的4取代的吡唑并吡啶类 |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| CN102241678B (zh) | 2011-04-26 | 2014-10-29 | 辽宁利锋科技开发有限公司 | 含有脂环结构化合物的抗肿瘤作用与应用 |
| SG11201500125QA (en) | 2012-07-11 | 2015-02-27 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
| EP2890815B1 (en) * | 2012-08-31 | 2019-03-20 | The Regents of the University of Colorado | Methods for diagnosis and treatment of cancer |
| WO2014055955A1 (en) | 2012-10-05 | 2014-04-10 | Rigel Pharmaceuticals, Inc. | Gdf-8 inhibitors |
| EP2914621B1 (en) | 2012-11-05 | 2023-06-07 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
| TWI629266B (zh) | 2012-12-28 | 2018-07-11 | 藍印藥品公司 | 纖維母細胞生長因子受體之抑制劑 |
| CA2899662A1 (en) * | 2013-02-01 | 2014-08-07 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolopyrimidinylamino-indazoles |
| CN103965199B (zh) | 2013-02-02 | 2017-07-07 | 广东东阳光药业有限公司 | 一种芳杂环化合物、包含它的药物组合物及其用途 |
| MX2015010700A (es) | 2013-02-21 | 2017-01-23 | Calitor Sciences Llc | Compuestos heteroaromaticos como moduladores de la p13 cinasa. |
| KR20150130491A (ko) | 2013-03-13 | 2015-11-23 | 제넨테크, 인크. | 피라졸로 화합물 및 그것의 용도 |
| WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| GB2515785A (en) * | 2013-07-03 | 2015-01-07 | Redx Pharma Ltd | Compounds |
| WO2015058129A1 (en) | 2013-10-17 | 2015-04-23 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| SI3057969T1 (sl) | 2013-10-17 | 2018-10-30 | Blueprint Medicines Corporation | Sestavki, uporabni za zdravljenje motenj, povezanih s KIT |
| RS63405B1 (sr) | 2013-10-25 | 2022-08-31 | Blueprint Medicines Corp | Inhibitori receptora faktora rasta fibroblasta |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| CN106536507B (zh) | 2014-04-08 | 2020-04-07 | 里格尔药品股份有限公司 | 作为TGF-β抑制剂的2,3-二取代的吡啶化合物及其使用方法 |
| US9688680B2 (en) | 2014-08-04 | 2017-06-27 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| CA2971024C (en) | 2014-12-15 | 2023-09-26 | Handok Inc. | Fused ring heteroaryl compounds and their use as trk inhibitors |
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| JP6800158B2 (ja) | 2015-02-20 | 2020-12-16 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｇｄｆ−８阻害剤 |
| CN108026102A (zh) | 2015-07-24 | 2018-05-11 | 蓝印药品公司 | 可用于治疗与kit和pdgfr相关的病症的化合物 |
| BR112018003588A2 (pt) | 2015-08-26 | 2018-09-25 | Blueprint Medicines Corp | compostos e composições úteis para tratamento de distúrbios relacionados ao ntrk |
| SI3371171T1 (sl) | 2015-11-02 | 2024-03-29 | Blueprint Medicines Corporation | Inhibitorji ret |
| SG10201912607SA (en) | 2015-11-19 | 2020-02-27 | Blueprint Medicines Corp | Compounds and compositions useful for treating disorders related to ntrk |
| US10183928B2 (en) | 2016-03-17 | 2019-01-22 | Blueprint Medicines Corporation | Inhibitors of RET |
| CN109311889B (zh) | 2016-04-15 | 2021-11-16 | 缆图药品公司 | 激活素受体样激酶抑制剂 |
| US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| WO2018022761A1 (en) | 2016-07-27 | 2018-02-01 | Blueprint Medicines Corporation | Substituted cyclopentane-amides for treating disorders related to ret |
| WO2018049233A1 (en) | 2016-09-08 | 2018-03-15 | Nicolas Stransky | Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors |
| CN107844168B (zh) | 2017-11-23 | 2020-12-01 | 英业达科技有限公司 | 主板组件及其卡扣装置 |
-
2016
- 2016-08-25 BR BR112018003588A patent/BR112018003588A2/pt not_active IP Right Cessation
- 2016-08-25 EP EP16763630.7A patent/EP3341374A1/en not_active Withdrawn
- 2016-08-25 MX MX2018002407A patent/MX2018002407A/es unknown
- 2016-08-25 AU AU2016311426A patent/AU2016311426B2/en not_active Expired - Fee Related
- 2016-08-25 WO PCT/US2016/048698 patent/WO2017035354A1/en not_active Ceased
- 2016-08-25 CA CA2995997A patent/CA2995997A1/en not_active Abandoned
- 2016-08-25 JP JP2018510406A patent/JP6877407B2/ja not_active Expired - Fee Related
- 2016-08-25 CN CN201680060799.0A patent/CN108137607B/zh not_active Expired - Fee Related
- 2016-08-25 RU RU2018110379A patent/RU2744974C2/ru active
- 2016-08-25 KR KR1020187008146A patent/KR20180043810A/ko not_active Withdrawn
- 2016-08-25 HK HK18114466.6A patent/HK1255330A1/zh unknown
- 2016-08-26 US US15/248,207 patent/US10017512B2/en active Active
- 2016-08-26 TW TW105127561A patent/TW201713665A/zh unknown
- 2016-08-26 AR ARP160102616A patent/AR105836A1/es unknown
-
2018
- 2018-02-22 PH PH12018500397A patent/PH12018500397A1/en unknown
- 2018-02-25 IL IL257702A patent/IL257702A/en unknown
- 2018-03-20 ZA ZA2018/01881A patent/ZA201801881B/en unknown
- 2018-07-03 US US16/027,166 patent/US11046697B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018528200A (ja) | 2018-09-27 |
| JP6877407B2 (ja) | 2021-05-26 |
| US20170066773A1 (en) | 2017-03-09 |
| WO2017035354A1 (en) | 2017-03-02 |
| AR105836A1 (es) | 2017-11-15 |
| US10017512B2 (en) | 2018-07-10 |
| HK1255330A1 (zh) | 2019-08-16 |
| RU2018110379A (ru) | 2019-09-27 |
| RU2018110379A3 (https=) | 2019-12-26 |
| AU2016311426B2 (en) | 2021-05-20 |
| EP3341374A1 (en) | 2018-07-04 |
| IL257702A (en) | 2018-04-30 |
| KR20180043810A (ko) | 2018-04-30 |
| ZA201801881B (en) | 2019-05-29 |
| PH12018500397A1 (en) | 2018-08-29 |
| MX2018002407A (es) | 2018-11-29 |
| CN108137607B (zh) | 2021-04-06 |
| US20190169194A1 (en) | 2019-06-06 |
| US11046697B2 (en) | 2021-06-29 |
| CA2995997A1 (en) | 2017-03-02 |
| CN108137607A (zh) | 2018-06-08 |
| TW201713665A (zh) | 2017-04-16 |
| RU2744974C2 (ru) | 2021-03-17 |
| AU2016311426A1 (en) | 2018-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018003588A2 (pt) | compostos e composições úteis para tratamento de distúrbios relacionados ao ntrk | |
| UY37134A (es) | Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4 | |
| BR112018008877A2 (pt) | inibidores de ret | |
| CO2018010459A2 (es) | Composiciones que comprenden cepas bacterianas | |
| UY37018A (es) | Inhibidores bicíclicos de pad4 | |
| BR112017020895A2 (pt) | inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer | |
| BR112018004620A2 (pt) | moduladores da expressão de kras | |
| SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
| MX2018006240A (es) | Composiciones que comprenden cepas bacterianas. | |
| BR112019006160A2 (pt) | composições e métodos para o tratamento das condições oftálmicas | |
| EA201891057A1 (ru) | Композиции и способы для ингибирования активности аргиназы | |
| BR112018009706A2 (pt) | composições compreendendo cepas bacterianas | |
| BR112018009213A2 (pt) | composições compreendendo cepas bacterianas | |
| MX380250B (es) | Compuestos farmacéuticos inhibidores de cinasa chk-1. | |
| BR112017025003A2 (pt) | composições compreendendo cepas bacterianas | |
| UY36357A (es) | Composiciones y métodos para la inhibición de la expresión génica de hao1 (hidroxiácido oxidasa 1 (glicolato oxidasa)) | |
| UY37017A (es) | Inhibidores aza-bencimidazol de pad4 | |
| EA201792496A1 (ru) | Способы лечения воспаления или нейропатической боли | |
| MX2019002190A (es) | Uso de pridopidina para tratar distonías. | |
| JOP20210158A1 (ar) | مُعَدِّلات التعبير الجيني عن hsd17b13 | |
| EA202091731A1 (ru) | Ингибиторы аутотаксина и их применения | |
| MX374654B (es) | Compuestos útiles para inhibir ror-gamma-t. | |
| CO2017001389A2 (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| EA201691549A1 (ru) | Ариллактамные ингибиторы киназы | |
| MX2017010654A (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2685 DE 21-06-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |